Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics


Rhythm Pharmaceuticals, Inc. (RYTM): $27.93

-1.60 (-5.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RYTM POWR Grades

  • RYTM scores best on the Growth dimension, with a Growth rank ahead of 46.47% of US stocks.
  • The strongest trend for RYTM is in Growth, which has been heading up over the past 179 days.
  • RYTM's current lowest rank is in the Quality metric (where it is better than 3.28% of US stocks).

RYTM Stock Summary

  • The ratio of debt to operating expenses for RHYTHM PHARMACEUTICALS INC is higher than it is for about just 5.35% of US stocks.
  • With a price/sales ratio of 99.85, RHYTHM PHARMACEUTICALS INC has a higher such ratio than 97.56% of stocks in our set.
  • Revenue growth over the past 12 months for RHYTHM PHARMACEUTICALS INC comes in at 1,146.45%, a number that bests 99.11% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RYTM, based on their financial statements, market capitalization, and price volatility, are FBIO, PRVB, APM, PXLW, and TDUP.
  • Visit RYTM's SEC page to see the company's official filings. To visit the company's web site, go to www.rhythmtx.com.

RYTM Valuation Summary

  • In comparison to the median Healthcare stock, RYTM's price/sales ratio is 1660.78% higher, now standing at 89.8.
  • RYTM's price/sales ratio has moved NA NA over the prior 65 months.

Below are key valuation metrics over time for RYTM.

Stock Date P/S P/B P/E EV/EBIT
RYTM 2023-01-30 89.8 5.3 -8.2 -7.0
RYTM 2023-01-27 98.3 5.8 -9.0 -7.8
RYTM 2023-01-26 103.0 6.1 -9.5 -8.2
RYTM 2023-01-25 104.8 6.2 -9.6 -8.3
RYTM 2023-01-24 105.3 6.2 -9.7 -8.4
RYTM 2023-01-23 100.1 5.9 -9.2 -7.9

RYTM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RYTM has a Quality Grade of F, ranking ahead of 2.46% of graded US stocks.
  • RYTM's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
  • EVOK, ATRA, and EVFM are the stocks whose asset turnover ratios are most correlated with RYTM.

The table below shows RYTM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.004 0.728 -0.232
2021-06-30 0.001 0.544 -0.211
2021-03-31 0.000 0.886 -0.196
2020-12-31 0.000 NA -0.922
2020-09-30 0.000 NA -0.718
2020-06-30 0.000 NA -0.784

RYTM Price Target

For more insight on analysts targets of RYTM, see our RYTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.67 Average Broker Recommendation 1.71 (Moderate Buy)

RYTM Stock Price Chart Interactive Chart >

Price chart for RYTM

RYTM Price/Volume Stats

Current price $27.93 52-week high $34.99
Prev. close $29.53 52-week low $3.04
Day low $27.82 Volume 330,100
Day high $29.83 Avg. volume 577,423
50-day MA $28.96 Dividend yield N/A
200-day MA $18.92 Market Cap 1.57B

Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio


Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.


RYTM Latest News Stream


Event/Time News Detail
Loading, please wait...

RYTM Latest Social Stream


Loading social stream, please wait...

View Full RYTM Social Stream

Latest RYTM News From Around the Web

Below are the latest news stories about RHYTHM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on February 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 24,525 shares of its common stock to f

Yahoo | February 8, 2023

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide - - Analysis published in Orphanet Journal of Rare Diseases - BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 recept

Yahoo | January 23, 2023

3 Breakout Growth Stocks to Buy for the Long Haul

Belite Bio (NASDAQ: BLTE), TransMedics Group (NASDAQ: TMDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM) set themselves apart over the past year with triple-digit share price gains. Each of the healthcare companies is developing something unique, whether it be finding treatments for maladies with no approved treatments, a more effective way to do organ transplants, or a more precise way to treat disorders that lead to obesity. Belite Bio is a clinical-stage biopharmaceutical company that focuses on therapies to treat blindness, diabetes, and liver disease.

Yahoo | January 9, 2023

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Call Transcript November 8, 2022 Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.79, expectations were $-1. Operator: Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2022 Earnings Conference Call. I would now like to hand the conference over to […]

Yahoo | December 30, 2022

12 Best Performing NASDAQ Stocks in 2022

In this article, we discuss 12 best performing NASDAQ stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing NASDAQ Stocks in 2022. The S&P 500 rose 0.6% to 3,844.82 on December 23, while the Nasdaq Composite gained 0.2% to close at 10,497.86. The Dow Jones Industrial […]

Yahoo | December 29, 2022

Read More 'RYTM' Stories Here

RYTM Price Returns

1-mo -13.64%
3-mo 6.04%
6-mo 28.12%
1-year 310.74%
3-year 56.65%
5-year 8.42%
YTD -4.09%
2022 191.78%
2021 -66.43%
2020 29.49%
2019 -14.58%
2018 -7.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8589 seconds.